摘要
目的探讨依达拉奉与灯盏花素注射液联合应用于急性缺血性脑血管病患者中的临床价值。方法选取2018年5月至2019年6月辽宁盘锦市人民医院收治的82例急性缺血性脑血管病患者作为研究对象,采用随机数字表法分为两组,其中对照组(n=41例)给予依达拉奉注射液治疗,观察组(n=41例)采用依达拉奉联合灯盏花素注射液治疗。比较两组患者临床疗效、血液流变学指标、内皮素-1(ET-1)、胰岛素抵抗指数(HOMA-IR)变化情况。结果观察组治疗有效率为90.24%,对照组治疗有效率为70.73%,差异有统计学意义(χ2=4.970,P=0.026)。治疗前,两组患者血液流变学指标比较,差异无统计学意义(P>0.05);治疗14 d后,观察组患者全血黏度、血浆黏度、纤维蛋白原、血细胞比容显著低于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者ET-1及HOMA-IR比较,差异无统计学意义(P>0.05);治疗14 d后,观察组患者ET-1、HOMA-IR显著低于对照组,差异有统计学意义(P<0.05)。结论依达拉奉与灯盏花素注射液联合应用于急性缺血性脑血管病中具有较高的临床价值,可显著改善患者的血液流变学指标,有效降低ET-1水平,抑制胰岛素抵抗。
Objective To investigate the clinical value of edaravone combined with breviscapine injection on patients with acute ischemic cerebrovascular disease. Methods A total of eighty-two patients with acute ischemic cerebrovascular disease admitted to Department of Neurology of Panjin People’s Hospital from May 2018 to June 2019 were selected as the research objects and were divided into two groups by random number table method. The control group(n=41 cases) was treated with edaravone injection.The observation group(n=41 cases) was treated with edaravone combined with breviscapine injection. The clinical efficacy, blood rheology indexes, endothelin-1(ET-1), insulin resistance index(HOMA-IR) changes between the two groups were compared. Results The effective rate of treatment in the observation group was 90.24%, and that in the control group was 70.73%, the difference was statistically significant(χ~2=4.970, P=0.026). There was no difference between the two groups of the changes of hemorheological indexes before treatment(P>0.05);after 14 d treatment, the whole blood viscosity, plasma viscosity, fibrinogen, and hematocrit of the observation group were significantly lower than those in the control group, and the difference was statistically significant(P<0.05). Before treatment, there was no significant difference in ET-1 and HOMA-IR between the two groups of patients(P>0.05). After 14 d treatment, ET-1、HOMA-IR of the patients in the observation group was significantly lower than that in the control group, the difference was statistically significant(P<0.05). Conclusion The edaravone combined with breviscapine injection has high clinical value in acute ischemic cerebral vessels disease, can significantly improve the hemorheological index of patients, effectively reduce ET-1 level and inhibit insulin resistance.
作者
韩莉娟
HAN Li-Juan(Emergency Department of Panjin People's Hospital,Panjin 124000,China)
出处
《中国药物经济学》
2020年第10期115-117,125,共4页
China Journal of Pharmaceutical Economics
